Migraine with aura identified as independent risk factor for A-fib
Related Articles
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.April 13, 2021
Mayo Clinic, Janssen-backed venture gets FDA OK for pulmonary hypertension AI algorithm
Becker's Hospital Review: A Mayo Clinic and Janssen-backed venture has received FDA breakthrough designation for an algorithm designed to enable early detection of pulmonary hypertension. Anumana Inc. received the breakthrough…May 23, 2022
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022